Related references
Note: Only part of the references are listed.Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis
Amal P. R. Samaraweera et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis
Amal P. R. Samaraweera et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
CD30+ cutaneous lymphoproliferative disorders with pseudocarcinomatous hyperplasia are associated with a T-helper-17 cytokine profile and infiltrating granulocytes
Joan Guitart et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Long-term effects of fingolimod in multiple sclerosis The randomized FREEDOMS extension trial
Ludwig Kappos et al.
NEUROLOGY (2015)
Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics
Cecilia Evangelisti et al.
ONCOTARGET (2014)
Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice
Kristina Berg Lorvik et al.
BLOOD (2012)
Melanoma Occurring During Treatment With Fingolimod for Multiple Sclerosis: A Case Report
Katrin Baumann Conzett et al.
ARCHIVES OF DERMATOLOGY (2011)
Evolving Insights in the Pathogenesis and Therapy of Cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary Syndrome)
Henry K. Wong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
Qing Liu et al.
BLOOD (2008)
The risk of lymphoma in patients with psoriasis
Joel M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Share Paper
